Zimbabwe has turned down a major US health deal worth 367 million US dollars (£272m) spanning five years because of Washington's insistence on sensitive information.
The decision was revealed after a official document dated December was leaked, indicating that President Emmerson Mnangagwa deemed the deal was "lopsided".
An official spokesperson has since clarified that the US was demanding access to genetic material for research and commercial purposes while refused to guarantee the benefits from future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for more talks to secure a agreement suitable to all parties so the nation's critical HIV programme can continue.
Broader Context
Zimbabwe's decision follows a similar situation in Kenya, where a court blocked a similar health funding agreement after concerns were raised about the safety of Kenyans' medical information.
After returning to office last year, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
The agency had administered assistance for the US government, but Trump claimed its spending was "wasteful" and his administration was seeking government-to-government deals to boost transparency and responsibility.
Based on reports, Sixteen nations in Africa have to date signed these new health pacts, constituting more than $18.3bn in new funding.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration could have provided significant benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy via US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to provide its biological resources and data over an extended period, with no corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"Put simply, our nation would supply the basic resources for medical research without any assurance that the resulting innovations would be available to our citizens if a future pandemic arise."
National Interest and Global Health
He also said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting structures already set up through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This framework is intended to ensure that when a nation contributes its information, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the capability to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our US partners on how subsequent co-operation could be designed in a manner that honours the sovereignty and dignity of both nations."
Medical Community Reaction
Medical experts stated it understood the official position, but urged that talks should continue given that a large portion of the country's HIV programmes were funded by foreign aid.
"In cases where specific concerns arise, including those relating to information security or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," the group commented.
The situation emphasises the complex challenges between receiving vital international aid and protecting a country's data in an ever more data-driven world.